During the COVID-19 pandemic, healthcare providers in areas where dengue is endemic need to consider dengue and COVID-19 in the differential diagnosis of acute febrile illnesses.
Most people with dengue and COVID-19 have mild illness and can recover at home; symptoms usually last a few days, and people tend to feel better after a week.
However, both dengue and COVID-19 can cause severe illness that can result in death.
The clinical management for people who develop severe illness with either of these two diseases is quite different, often requiring hospital-based care.
Find out below the clinical differences in common clinical information.
Viral characteristics
• Viral titer correlates with
disease severity
• There may be strain and
serotype differences in pathogenicity
Host factors
• Age (infant)
• Women, especially pregnant
women
• Patients with chronic medical
conditions, including diabetes, asthma, obesity, and heart disease
• Patients with secondary DENV
infection
Level of neutralizing antibody
• Timing of infection relative to
the previous DENV infection (the longer, the higher the risk)
• There are no tests or
biomarkers to identify which patients will experience severe disease
Some people are more likely than
others to become severely ill.
People at increased risk, and those who live or visit with them, need to take precautions to protect themselves from getting COVID-19.
·
Older Adults
·
People with Certain Medical Conditions
Cancer.
Chronic kidney
disease.
Chronic lung
diseases, including COPD (chronic obstructive pulmonary disease), asthma
(moderate-to-severe), interstitial lung disease, cystic fibrosis, and pulmonary
hypertension.
Dementia.
Diabetes (type 1
or type 2).
Heart conditions
(such as heart failure, coronary artery disease, cardiomyopathies or
hypertension).
Down syndrome.
Immunocompromised
state.
HIV infection.
Liver disease.
Overweight and
obesity.
Smoking.
Solid organ or
blood stem cell transplant.
Stroke or cerebrovascular disease.
· Pregnant and Recently Pregnant People
Healthcare providers should
perform appropriate tests (for Dengue; for COVID-19) and follow the
patient closely for warning signs.
Dengue |
COVID-19 |
Transmission |
|
Dengue, an illness caused by
any of 4 dengue viruses, is mainly transmitted to people through the bites of
infected Aedes species mosquitoes (primarily Ae. aegypti or Ae. albopictus
species). |
COVID-19, a respiratory illness
caused by the virus SARS-CoV-2, is mainly transmitted from person to person
through respiratory droplets that are spread when an infected person coughs,
sneezes, or talks. |
Incubation Period |
|
The incubation period for
dengue ranges between 3-10 days, typically 5-7 days. |
The incubation period for
COVID-19 is thought to extend to 14 days, with a median of 4-5 days from
exposure to symptoms onset. |
Clinical Course |
Dengue |
COVID-19 |
|
|
Mild to moderate disease Febrile phase
Critical Phase Warning signs may appear, and rapid clinical
deterioration may occur within 48 hours after defervescence (3–7 days after
fever onset). |
Mild to moderate disease
NOTE: These signs
and symptoms of COVID-19 are the ones most persons with the illness have
experienced. However, this list is not inclusive. |
Severe Illness |
|
Severe dengue is defined by dengue with any of the
following symptoms and signs:
|
Among patients who developed severe disease, the medium time to dyspnea
ranged from 5 to 8 days, the median time to acute respiratory distress
syndrome (ARDS) ranged from 8 to 12 days, and the median time to ICU
admission ranged from 10 to 12 days. Signs and symptoms for severe illness can include:
Clinicians should be aware
of the potential for some patients to rapidly deteriorate one week after
illness onset. |
https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/index.html
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7536968/figure/rmv2161-fig-0001/
Note: For informational purposes only. Consult your
textbook for advising your patients.
Comments
You must login to write comment